Welcome to our dedicated page for Relay Therapeutics news (Ticker: RLAY), a resource for investors and traders seeking the latest updates and insights on Relay Therapeutics stock.
Relay Therapeutics, Inc. (NASDAQ: RLAY) is a clinical-stage precision medicine company dedicated to transforming the drug discovery process. Headquartered in Cambridge, Massachusetts, the company focuses on combining advanced computational and experimental technologies to develop life-changing therapies. Since its inception in 2016, Relay Therapeutics has been pioneering a new paradigm in the pharmaceutical industry by placing protein motion at the core of drug discovery.
The company's flagship platform, Dynamo™, integrates cutting-edge computational and experimental approaches to target protein structures that are either intractable or inadequately addressed by current therapies. This platform has enabled the development of multiple promising drug candidates, particularly in the fields of precision oncology and genetic diseases. Key product candidates include RLY-4008, RLY-2608, and GDC-1971 (formerly RLY-1971).
Relay Therapeutics' recent corporate highlights include significant advancements in its RLY-2608 program, aimed at treating patients with PI3Kα-mutated HR+/HER2- breast cancer. The company's development pipeline has been robust, with expectations to disclose innovative programs later this year.
Financially, as of March 31, 2024, Relay Therapeutics reported cash, cash equivalents, and investments totaling approximately $749.6 million. This financial stability is projected to fund the company's operations into the second half of 2026. The company’s revenue for Q1 2024 was $10 million, primarily derived from milestone payments under a collaboration agreement with Genentech, Inc.
Relay Therapeutics has also established strategic partnerships with notable entities such as Pfizer, Nextech, and Genentech, enhancing its capability to advance its clinical and preclinical programs. The company’s innovative approach has attracted significant investment from third-party ventures, including GV (formerly Google Ventures) and Alexandria Venture Investments.
Relay Therapeutics continues to push the boundaries of what’s possible in drug discovery, aiming to improve the lives of millions of patients through precision medicine.
Relay Therapeutics (Nasdaq: RLAY) will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 2:15 p.m. PT. The event will be webcast live, accessible via Relay Therapeutics' website under the News & Events section. An archived version will be available for 30 days post-event. Relay Therapeutics is a clinical-stage precision medicine company, innovating drug discovery using its Dynamo™ platform to target challenging protein targets, focusing on oncology and genetic diseases.
Relay Therapeutics (Nasdaq: RLAY) will participate in two key conferences in November 2022. The H.C. Wainwright 3rd Annual Precision Oncology Virtual Conference is on November 14 at 10:00 a.m. ET, followed by the Stifel 2022 Healthcare Conference on November 16 at 1:15 p.m. ET. Both events will be accessible via live webcast on Relay Therapeutics' website, with archived replays available for 30 days post-presentation. Relay Therapeutics is a clinical-stage precision medicine company focusing on drug discovery using advanced technologies.
Relay Therapeutics reported strong interim results for RLY-4008, showing an 88% overall response rate among FGFR2-fusion cholangiocarcinoma patients at the ESMO Congress. This supports the potential of their Dynamo platform in developing therapies for FGFR2-driven tumors. The company also reported $1.1 billion in cash and equivalents, sufficient to fund operations into 2025. However, R&D expenses rose to $66.9 million, leading to a net loss of $84.2 million for Q3 2022. Relay continues to focus on advancing its clinical trials and therapies.
Relay Therapeutics (Nasdaq: RLAY) plans to release its third quarter 2022 financial results and corporate highlights on November 3, 2022, after market close. The company specializes in precision medicine, utilizing advanced computational and experimental technologies in drug discovery. Notably, it aims to tackle complex protein targets through its Dynamo™ platform. Notably, no teleconference will follow the financial results release.
Relay Therapeutics (Nasdaq: RLAY) is set to participate in a virtual fireside chat at the Bank of America Securities 2022 Precision Oncology Conference on October 3, 2022, at 2:50 p.m. ET. The event will be webcast live and can be accessed via Relay Therapeutics’ website. An archived replay will be available for up to 30 days after the presentation. Relay Therapeutics focuses on transforming drug discovery using its Dynamo™ platform, aimed at enhancing small molecule therapeutic discovery in oncology and genetic diseases.
Relay Therapeutics (Nasdaq: RLAY) announced a public offering of 11,320,755 shares at $26.50 each, aiming to raise approximately $300 million before expenses. An additional 1,698,113 shares may be purchased by underwriters within 30 days. The offering, managed by Goldman Sachs, J.P. Morgan, and Cowen, is set to close around September 15, 2022. This financing effort is part of Relay's strategy to enhance drug discovery capabilities, focusing on targeted oncology and genetic diseases.
Relay Therapeutics (Nasdaq: RLAY) has announced a public offering of $300 million in common stock, with an option for underwriters to buy an additional 15%. This offering is part of a strategy to enhance its capital position for advancing its precision medicine initiatives in drug discovery. The proposed shares are being sold solely by Relay Therapeutics and will be offered under an effective shelf registration statement previously filed with the SEC. Major banks involved include Goldman Sachs, J.P. Morgan, and Cowen.
Relay Therapeutics (Nasdaq: RLAY) has announced a collaboration with Foundation Medicine to develop FoundationOne®CDx as a companion diagnostic for RLY-4008, an investigational FGFR2 inhibitor targeting cholangiocarcinoma. Interim clinical data presented at ESMO 2022 showed an 88% overall response rate in patients with FGFR2 mutations. The partnership aims to enable more effective treatments for patients with aggressive conditions, expanding access to precision medicine.
Relay Therapeutics (Nasdaq: RLAY) announced promising interim clinical results for RLY-4008, a selective FGFR2 inhibitor, achieving an 88% overall response rate in FGFRi-naïve FGFR2-fusion cholangiocarcinoma patients. Data were presented at the ESMO Congress, reflecting results from 17 patients as of August 1, 2022. The pivotal cohort enrollment is expected to wrap up in the second half of 2023. The company is also gearing up to reveal further data on RLY-2608, a pan-mutant selective PI3Kα inhibitor, within the next year.
Relay Therapeutics announced that an interim clinical data abstract for RLY-4008 has been selected for an oral presentation at the ESMO Congress on September 11, 2022. The focus will be on dose escalation in patients with FGFR2 fusion cholangiocarcinoma. The company will hold a conference call on September 12, 2022, at 8:00 am E.T. to discuss these results. RLY-4008 is a selective oral inhibitor of FGFR2, showing preclinical efficacy against cancer cell lines and is presently under evaluation in a clinical trial for advanced FGFR2-altered solid tumors.
FAQ
What is the current stock price of Relay Therapeutics (RLAY)?
What is the market cap of Relay Therapeutics (RLAY)?
What is Relay Therapeutics' primary focus?
Where is Relay Therapeutics headquartered?
What is the Dynamo™ platform?
What are some of Relay Therapeutics' key product candidates?
How financially stable is Relay Therapeutics?
Which significant partnerships has Relay Therapeutics established?
What recent progress has Relay Therapeutics made?
How does Relay Therapeutics plan to use its financial resources?
When was Relay Therapeutics founded?
What makes Relay Therapeutics' approach unique?
